Cargando…

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()

OBJECTIVE: To describe medroxyprogesterone acetate (MPA) levels among Kenyan depot medroxyprogesterone acetate (DMPA) users in the FEM-PrEP HIV prevention trial, and to compare MPA levels between ARV for HIV prevention (treatment) and placebo groups. STUDY DESIGN: We measured MPA in previously colle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nanda, Kavita, Callahan, Rebecca, Taylor, Douglas, Wang, Meng, Agot, Kawango, Jenkins, David, Van Damme, Lut, Dorflinger, Laneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894753/ https://www.ncbi.nlm.nih.gov/pubmed/26972780 http://dx.doi.org/10.1016/j.contraception.2016.03.003

Ejemplares similares

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial
por: Corneli, Amy, et al.
Publicado: (2015)

A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation()
por: Halpern, Vera, et al.
Publicado: (2023)

Incidence of Galactorrhea in Young Women Using Depot-Medroxyprogesterone Acetate
por: Omar, Hatim A., et al.
Publicado: (2006)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma
por: Harmon, Quaker E., et al.
Publicado: (2022)

Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera
por: Halpern, Vera, et al.
Publicado: (2021)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

The Sexual Risk Context among the FEM-PrEP Study Population in Bondo, Kenya and Pretoria, South Africa
por: Headley, Jennifer, et al.
Publicado: (2014)

An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)()()
por: Katz, Micah, et al.
Publicado: (2020)

The potential for intramuscular depot medroxyprogesterone acetate as a self-bridging emergency contraceptive()
por: Schickler, Robyn, et al.
Publicado: (2020)

Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
por: Yuasa-Shibasaki, Erina, et al.
Publicado: (2017)

Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression
por: Morrison, Charles S., et al.
Publicado: (2020)

Increased Cervical CD4(+)CCR5(+) T Cells Among Kenyan Sex Working Women Using Depot Medroxyprogesterone Acetate
por: Lajoie, Julie, et al.
Publicado: (2019)

Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report
por: Malahleha, Mookho, et al.
Publicado: (2015)

FEM-PrEP: Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Pre-exposure Prophylaxis
por: Corneli, Amy L., et al.
Publicado: (2014)

High-risk sexual behaviors while on depot medroxyprogesterone acetate as compared to oral contraception
por: Bartz, Deborah, et al.
Publicado: (2017)

Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review
por: Silva, P., et al.
Publicado: (2018)

Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
por: Upson, Kristen, et al.
Publicado: (2020)

An updated review on the effects of depot medroxyprogesterone acetate on the mucosal biology of the female genital tract
por: Ayele, Hossaena, et al.
Publicado: (2021)

Multi-omics analysis of the cervical epithelial integrity of women using depot medroxyprogesterone acetate
por: Bradley, Frideborg, et al.
Publicado: (2022)

Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials
por: Agot, Kawango, et al.
Publicado: (2014)

Counting the costs: Comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa
por: Smit, Jennifer, et al.
Publicado: (2001)

Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report
por: Walker, Christie, et al.
Publicado: (2013)

Successful treatment of Depot Medroxyprogesterone acetate-related vaginal bleeding improves continuation rates in Adolescents
por: Rager, Kristin M., et al.
Publicado: (2006)

Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility
por: Smith-McCune, K K, et al.
Publicado: (2017)

Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women
por: Yang, Liying, et al.
Publicado: (2019)

Update on the Impact of Depot Medroxyprogesterone Acetate on Vaginal Mucosal Endpoints and Relevance to Sexually Transmitted Infections
por: Dabee, Smritee, et al.
Publicado: (2023)

Differential Elevation of Inflammation and CD4(+) T Cell Activation in Kenyan Female Sex Workers and Non-Sex Workers Using Depot-Medroxyprogesterone Acetate
por: Omollo, Kenneth, et al.
Publicado: (2021)

Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant
por: Deese, Jennifer, et al.
Publicado: (2021)

A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD
por: Fathizadeh, Nahid, et al.
Publicado: (2011)

Scaling up depot medroxyprogesterone acetate (DMPA): a systematic literature review illustrating the AIDED model
por: Curry, Leslie, et al.
Publicado: (2013)

Protective Effect of Vitamins C and E on Depot-Medroxyprogesterone Acetate-Induced Ovarian Oxidative Stress In Vivo
por: Ismiyati, Atik, et al.
Publicado: (2016)

Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial()()()()
por: Chinula, Lameck, et al.
Publicado: (2018)

Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results
por: Okegbe, Tishina, et al.
Publicado: (2019)

Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices
por: Birse, Kenzie D., et al.
Publicado: (2017)

Exploring the immunomodulatory role of depot medroxyprogesterones acetate and endogenous progesterone levels in HIV infected and uninfected women
por: Mnqonywa, Nonzwakazi, et al.
Publicado: (2019)

Changes in key vaginal bacteria among postpartum African women initiating intramuscular depot-medroxyprogesterone acetate
por: Whitney, Bridget M., et al.
Publicado: (2020)

Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
por: Wessels, Jocelyn M., et al.
Publicado: (2021)

A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment
por: Francis, Jose, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5vf5okm5e2kp97bp4hknvinc14